Glycyrrhizin protects against porcine endotoxemia through modulation of systemic inflammatory response

Critical Care

Volumn 17, Issue 2, 2013, Pages

  Wang, Wei ^a   Zhao, Feng ^a   Fang, Yong ^a   Li, Xiantao ^a   Shen, Lei ^a   Cao, Tongwa ^a   Zhu, Hechen ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATININE; CYTOKINE; GLYCYRRHIZIC ACID; HEMOGLOBIN; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; PYRUVIC ACID; PYRUVIC ACID ETHYL ESTER; SODIUM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; AUTACOID; PROTECTIVE AGENT;

ANESTHESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL VENTILATION; BLOOD GAS ANALYSIS; CENTRAL VENOUS PRESSURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE RELEASE; DRUG EFFECT; ENDOTOXEMIA; ENZYME ASSAY; ERYTHROCYTE; FEMALE; GENE EXPRESSION; HEART RATE; HEMATOLOGICAL PARAMETERS; HEMODYNAMICS; HISTOPATHOLOGY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY PARENCHYMA; LEUKOCYTE; LIVER; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG PARENCHYMA; LUNG WEDGE PRESSURE; LYMPH NODE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; OXYGEN TRANSPORT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTHROMBIN TIME; REAL TIME POLYMERASE CHAIN REACTION; SMALL INTESTINE; SODIUM BLOOD LEVEL; SWAN GANZ CATHETER; SWINE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THERMODILUTION DEVICE; THROMBOCYTE COUNT; WESTERN BLOTTING; ANIMAL; BLOOD; MINIPIG; PATHOLOGY; PIG; RANDOMIZATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ENDOTOXEMIA; FEMALE; GLYCYRRHIZIC ACID; INFLAMMATION MEDIATORS; MALE; PROTECTIVE AGENTS; RANDOM ALLOCATION; SWINE; SWINE, MINIATURE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84874672440     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc12558     Document Type: Article

References (42)

1. Asfar P, Hauser B, Iványi Z, Ehrmann U, Kick J, Albicini M, Vogt J, Wachter U, Brückner UB, Radermacher P, Bracht H. Low-dose terlipressin during long-term hyperdynamic porcine endotoxemia: effects on hepatosplanchnic perfusion, oxygen exchange, and metabolism. Crit Care Med 2005, 33:373-380. 10.1097/01.CCM.0000152253.45901.FB, 15699842.
2. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008, 8:776-787. 10.1038/nri2402, 2786961, 18802444.
3. An G, Namas RA, Vodovotz Y. Sepsis: from pattern to mechanism and back. Crit Rev Biomed Eng 2012, 40:341-351. 10.1615/CritRevBiomedEng.v40.i4.80, 23140124.
4. Ianaro A, Tersigni M, D'Acquisto F. New insight in LPS antagonist. Mini Rev Med Chem 2009, 9:306-317. 10.2174/1389557510909030306, 19275723.
5. Yan T, Li Q, Zhou H, Zhao Y, Yu S, Xu G, Yin Z, Li Z, Zhao Z. Gu-4 suppresses affinity and avidity modulation of CD11b and improves the outcome of mice with endotoxemia and sepsis. PLoS One 2012, 7:e30110. 10.1371/journal.pone.0030110, 3271073, 22319560.
6. Zhu S, Li W, Ward MF, Sama AE, Wang H. High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation. Inflamm Allergy Drug Targets 2010, 9:60-72. 10.2174/187152810791292872, 2866444, 19906009.
7. Youn JH, Oh YJ, Kim ES, Choi JE, Shin JS. High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-alpha production in human monocytes. J Immunol 2008, 180:5067-5074.
8. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251. 10.1126/science.285.5425.248, 10398600.
9. Bianchi ME. HMGB1 loves company. J Leukoc Biol 2009, 86:573-576. 10.1189/jlb.1008585, 19414536.
10. Sappington PL, Yang R, Yang H, Tracey KJ, Delude RL, Fink MP. HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology 2002, 123:790-802. 10.1053/gast.2002.35391, 12198705.
11. Naglova H, Bucova M. HMGB1 and its physiological and pathological roles. Bratisl Lek Listy 2012, 113:163-171.
12. Qin YH, Dai SM, Tang GS, Zhang J, Ren D, Wang ZW, Shen Q. HMGB1 enhances the proinflammatory activity of lipopolysaccharide by promoting the phosphorylation of MAPK p38 through receptor for advanced glycation end products. J Immunol 2009, 183:6244-6250. 10.4049/jimmunol.0900390, 19890065.
13. Fink MP. Ethyl pyruvate. Curr Opin Anaesthesiol 2008, 21:160-167. 10.1097/ACO.0b013e3282f63c2e, 18443482.
14. Bennett-Guerrero E, Swaminathan M, Grigore AM, Roach GW, Aberle LG, Johnston JM, Fink MP. A phase II multicenter double-blind placebo-controlled study of ethyl pyruvate in high-risk patients undergoing cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2009, 23:324-329. 10.1053/j.jvca.2008.08.005, 18835526.
15. Wang H, Li W, Li J, Rendon-Mitchell B, Ochani M, Ashok M, Yang L, Yang H, Tracey KJ, Wang P, Sama AE. The aqueous extract of a popular herbal nutrient supplement, Angelica sinensis, protects mice against lethal endotoxemia and sepsis. J Nutr 2006, 136:360-365. 1766946, 16424112.
16. Wheeler DS, Lahni PM, Hake PW, Denenberg AG, Wong HR, Snead C, Catravas JD, Zingarelli B. The green tea polyphenol epigallocatechin-3-gallate improves systemic hemodynamics and survival in rodent models of polymicrobial sepsis. Shock 2007, 28:353-359. 10.1097/shk.0b013e3180485823, 17545942.
17. Li W, Ashok M, Li J, Yang H, Sama AE, Wang H. A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1. PLoS One 2007, 2:e1153. 10.1371/journal.pone.0001153, 2048740, 17987129.
18. Cheng TO. Cardiovascular effects of Danshen. Int J Cardiol 2007, 121:9-22. 10.1016/j.ijcard.2007.01.004, 17363091.
19. Fiore C, Eisenhut M, Ragazzi E, Zanchin G, Armanini D. A history of the therapeutic use of liquorice in Europe. J Ethnopharmacol 2005, 99:317-324. 10.1016/j.jep.2005.04.015, 15978760.
20. Gwak GY, Moon TG, Lee DH, Yoo BC. Glycyrrhizin attenuates HMGB1-induced hepatocyte apoptosis by inhibiting the p38-dependent mitochondrial pathway. World J Gastroenterol 2012, 18:679-684. 10.3748/wjg.v18.i7.679, 3281226, 22363140.
21. Ohnishi M, Katsuki H, Fukutomi C, Takahashi M, Motomura M, Fukunaga M, Matsuoka Y, Isohama Y, Izumi Y, Kume T, Inoue A, Akaike A. HMGB1 inhibitor glycyrrhizin attenuates intracerebral hemorrhage-induced injury in rats. Neuropharmacology 2011, 61:975-980. 10.1016/j.neuropharm.2011.06.026, 21752338.
22. Mollica L, De Marchis F, Spitaleri A, Dallacosta C, Pennacchini D, Zamai M, Agresti A, Trisciuoglio L, Musco G, Bianchi ME. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol 2007, 14:431-441. 10.1016/j.chembiol.2007.03.007, 17462578.
23. Shi JR, Mao LG, Jiang RA, Qian Y, Tang HF, Chen JQ. Monoammonium glycyrrhizinate inhibited the inflammation of LPS-induced acute lung injury in mice. Int Immunopharmacol 2010, 10:1235-1241. 10.1016/j.intimp.2010.07.004, 20637836.
24. Asl MN, Hosseinzadeh H. Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother Res 2008, 22:709-724. 10.1002/ptr.2362, 18446848.
25. Korenaga M, Hidaka I, Nishina S, Sakai A, Shinozaki A, Gondo T, Furutani T, Kawano H, Sakaida I, Hino K. A glycyrrhizin-containing preparation reduces hepatic steatosis induced by hepatitis C virus protein and iron in mice. Liver Int 2011, 31:552-560. 10.1111/j.1478-3231.2011.02469.x, 21382166.
26. Nalos M, Vassilev D, Pittner A, Asfar P, Bruckner UB, Schneider EM, Georgieff M, Radermacher P, Froeba G. Tin-mesoporphyrin for inhibition of heme oxygenase during long-term hyperdynamic porcine endotoxemia. Shock 2003, 19:526-532. 10.1097/01.shk.0000070732.34700.07, 12785007.
27. Kubiak BD, Albert SP, Gatto LA, Snyder KP, Maier KG, Vieau CJ, Roy S, Nieman GF. Peritoneal negative pressure therapy prevents multiple organ injury in a chronic porcine sepsis and ischemia/reperfusion model. Shock 2010, 34:525-534. 10.1097/SHK.0b013e3181e14cd2, 20823698.
28. Evennett NJ, Petrov MS, Mittal A, Windsor JA. Systematic review and pooled estimates for the diagnostic accuracy of serological markers for intestinal ischemia. World J Surg 2009, 33:1374-1383. 10.1007/s00268-009-0074-7, 19424744.
29. Hou Y, Wang L, Zhang W, Yang Z, Ding B, Zhu H, Liu Y, Qiu Y, Yin Y, Wu G. Protective effects of N-acetylcysteine on intestinal functions of piglets challenged with lipopolysaccharide. Amino Acids 2012, 43:1233-1242. 10.1007/s00726-011-1191-9, 22180025.
30. Imtiaz KE. Sweet root, bitter pill: liquorice-induced hyperaldosteronism. QJM 2011, 104:1093-1095. 10.1093/qjmed/hcq233, 21131288.
31. Sasaki H, Suzuki N, Alshwaimi E, Xu Y, Battaglino R, Morse L, Stashenko P. 18beta-glycyrrhetinic acid inhibits periodontitis via glucocorticoid-independent nuclear factor-kappaB inactivation in interleukin-10-deficient mice. J Periodontal Res 2010, 45:757-763. 10.1111/j.1600-0765.2010.01296.x, 3075584, 20682015.
32. Chien CF, Wu YT, Tsai TH. Biological analysis of herbal medicines used for the treatment of liver diseases. Biomed Chromatogr 2011, 25:21-38. 10.1002/bmc.1568, 21204110.
33. Menegazzi M, Di Paola R, Mazzon E, Genovese T, Crisafulli C, Dal Bosco M, Zou Z, Suzuki H, Cuzzocrea S. Glycyrrhizin attenuates the development of carrageenan-induced lung injury in mice. Pharmacol Res 2008, 58:22-31. 10.1016/j.phrs.2008.05.012, 18590825.
34. Sun Y, Cai TT, Shen Y, Zhou XB, Chen T, Xu Q. Si-Ni-San, a traditional Chinese prescription, and its active ingredient glycyrrhizin ameliorate experimental colitis through regulating cytokine balance. Int Immunopharmacol 2009, 9:1437-1443. 10.1016/j.intimp.2009.08.017, 19733696.
35. Genovese T, Menegazzi M, Mazzon E, Crisafulli C, Di Paola R, Dal Bosco M, Zou Z, Suzuki H, Cuzzocrea S. Glycyrrhizin reduces secondary inflammatory process after spinal cord compression injury in mice. Shock 2009, 31:367-375. 10.1097/SHK.0b013e3181833b08, 18665052.
36. Honda H, Nagai Y, Matsunaga T, Saitoh S, Akashi-Takamura S, Hayashi H, Fujii I, Miyake K, Muraguchi A, Takatsu K. Glycyrrhizin and isoliquiritigenin suppress the LPS sensor Toll-like receptor 4/MD-2 complex signaling in a different manner. J Leukoc Biol 2012, 91:967-976. 10.1189/jlb.0112038, 22422925.
37. Wang CY, Kao TC, Lo WH, Yen GC. Glycyrrhizic acid and 18beta-glycyrrhetinic acid modulate lipopolysaccharide-induced inflammatory response by suppression of NF-kappaB through PI3K p110delta and p110gamma inhibitions. J Agric Food Chem 2011, 59:7726-7733. 10.1021/jf2013265, 21644799.
38. Scumpia PO, Moldawer LL. Biology of interleukin-10 and its regulatory roles in sepsis syndromes. Crit Care Med 2005, 33:S468-471. 10.1097/01.CCM.0000186268.53799.67, 16340424.
39. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 2006, 25:6680-6684. 10.1038/sj.onc.1209954, 17072321.
40. Roman-Blas JA, Jimenez SA. Targeting NF-kappaB: a promising molecular therapy in inflammatory arthritis. Int Rev Immunol 2008, 27:351-374. 10.1080/08830180802295740, 18853343.
41. Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999, 274:19919-19924. 10.1074/jbc.274.28.19919, 10391939.
42. Yaser AM, Huang Y, Zhou RR, Hu GS, Xiao MF, Huang ZB, Duan CJ, Tian W, Tang DL, Fan XG. The role of receptor for advanced glycation end products (RAGE) in the proliferation of hepatocellular carcinoma. Int J Mol Sci 2012, 13:5982-5997. 10.3390/ijms13055982, 3382819, 22754344.